Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that Molina Healthcare failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and the company's financial guidance for fiscal year 2025 [5]. - It is claimed that these undisclosed facts led to misleading statements about Molina's business operations and prospects, resulting in investor damages when the truth was revealed [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. for alleged violations of federal securities laws, encouraging affected investors to participate in a class action lawsuit [2][5]. Summary by Sections Legal Action - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may have the opportunity to lead a class action lawsuit against the company [1][2]. - The deadline to seek the role of lead plaintiff in the federal securities class action is December 2, 2025 [2]. Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements regarding: 1. Material adverse facts about the company's medical cost trend assumptions [5]. 2. A dislocation between premium rates and medical cost trends [5]. 3. Dependency on low utilization of behavioral health, pharmacy, and inpatient and outpatient services for near-term growth [5]. 4. Likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. 5. Misleading positive statements about the company's business and operations [5]. Financial Performance - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [6][7]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50 [7]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share [7]. - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year [8]. - The new guidance for full-year 2025 adjusted earnings was set at no less than $19.00 per diluted share, reflecting a 13.6% cut from previous guidance [8]. - Molina's stock price dropped by $32.03, or 16.84%, closing at $158.22 per share following this announcement [8].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 2, 2025 deadline for a securities class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors in previous years [4]. Group 3: Case Specifics - The lawsuit claims that Molina's financial guidance for fiscal year 2025 was likely to be cut due to undisclosed adverse facts, which included issues with medical cost trend assumptions and a dislocation between premium rates and medical costs [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, of the December 2, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Molina securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 2, 2025, to serve as lead plaintiff [2] - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [4] Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3] - The firm has been recognized for its leadership in securities class action settlements, achieving significant recoveries for investors in previous years [3] Group 3: Case Specifics - The lawsuit claims that Molina's financial guidance for fiscal year 2025 was likely to be cut due to undisclosed adverse facts, which included issues with medical cost trend assumptions and reliance on limited service utilization [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [1][3]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements regarding the company's medical cost trend assumptions and failed to disclose adverse facts affecting its financial outlook [3]. - Specific issues cited include a dislocation between premium rates and medical costs, reliance on low utilization of services, and the likelihood of substantial cuts to financial guidance for fiscal year 2025 [3]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter results, reporting adjusted earnings of approximately $5.50 per share, which was below expectations, leading to a 10.2% cut in full-year earnings guidance from at least $24.50 to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [4]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year, and cutting guidance for full-year adjusted earnings to no less than $19.00 per diluted share, a 13.6% reduction [5]. - This led to a significant drop in Molina's stock price by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [5].

Core Viewpoint - Molina Healthcare, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 5, 2025, and July 23, 2025, which has adversely affected investors [1][2]. Group 1: Allegations and Impact - The lawsuit claims that the defendants made false statements and concealed material adverse facts regarding the company's medical cost trend assumptions [2]. - It is alleged that Molina was experiencing a dislocation between premium rates and medical cost trends, which could lead to a significant cut in the company's financial guidance for fiscal year 2025 [2]. - The lawsuit suggests that Molina's near-term growth was reliant on a lack of utilization of behavioral health, pharmacy, and inpatient and outpatient services, which misled investors about the company's business prospects [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until December 2, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating a no-cost participation in the lawsuit [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [2][6]. Group 1: Class Action Details - The class action pertains to Molina securities purchased between February 5, 2025, and July 23, 2025, with a lead plaintiff deadline set for December 2, 2025 [2][4]. - Investors who purchased Molina securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. Group 2: Allegations Against Molina - The lawsuit alleges that Molina failed to disclose material adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [6]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a substantial cut in the company's financial guidance for fiscal year 2025 [6]. - The lawsuit asserts that positive statements made by Molina regarding its business and prospects were materially misleading and lacked a reasonable basis [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [5]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [5].

Core Viewpoint - Molina Healthcare, Inc. is facing a class action securities lawsuit due to alleged securities fraud that negatively impacted investors between February 5, 2025, and July 23, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false statements regarding Molina's "medical cost trend assumptions" and concealed adverse facts about the company's financial health [2]. - It is alleged that Molina was experiencing a dislocation between premium rates and medical costs, which could lead to a significant cut in the company's financial guidance for fiscal year 2025 [2]. - Following the revelation of these issues, Molina's stock price experienced a decline [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until December 2, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Points - Molina Healthcare, Inc. has successfully closed an offering of $850 million in senior notes with a 6.500% interest rate, maturing in 2031 [1] Group 1 - The offering was made to qualified institutional buyers under Rule 144A of the Securities Act of 1933 [1] - The notes were also offered to certain non-U.S. persons outside the United States [1]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Molina Healthcare, Inc. regarding a class action lawsuit due to alleged false statements and material omissions that negatively impacted the company's stock price [1]. Summary by Sections Allegations - Defendants allegedly made false statements and concealed material adverse facts about Molina's "medical cost trend assumptions" [1]. - It was claimed that Molina was facing a "dislocation between premium rates and medical cost trend" [1]. - The company's near-term growth was reportedly reliant on reduced utilization of behavioral health, pharmacy, and inpatient and outpatient services [1]. - As a result of these issues, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced [1]. - The positive statements made by defendants regarding Molina's business and prospects were deemed materially misleading or lacking a reasonable basis [1]. Class Action Details - The class period for the lawsuit is from February 5, 2025, to July 23, 2025 [1]. - Shareholders are encouraged to register for the class action by December 2, 2025, to potentially be appointed as lead plaintiffs [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors affected by deceit, fraud, and illegal business practices [3]. - The firm is committed to ensuring companies engage in responsible business practices and good corporate citizenship [3]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that led to artificial inflation of stock prices [3].